Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels

Table 3

Comparison of adverse reactions.

	Gastrointestinal reaction	Leukopenia	Thrombocytopenia	Peripheral neurotoxicity	Liver function injury	Renal function injury	Myelosuppression	Fever	Overall incidence
Control group (n = 65)	5 (7.6)	3 (4.6)	4 (6.2)	2 (3.1)	2 (3.1)	2 (3.1)	3 (4.6)	3 (4.6)	24 (36.9)
Combination group (n = 76)	4 (5.3)	2 (2.6)	4 (5.3)	2 (2.6)	3 (3.9)	2 (2.6)	2 (2.6)	4 (5.3)	23 (30.2)
χ ^2	0.3460	0.4031	0.0519	0.0252	0.0776	0.0252	0.4031	0.0312	0.6993
	0.5564	0.5255	0.8197	0.8738	0.7806	0.8738	0.5255	0.8599	0.4030